AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27858951
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy fall reduction home visit program (IG)
Trial: 21325226
Drug: Probiotic culture
RxNorm normalized name: Lactobacillus Reuteri/Lactobacillus rhamnosus/Probiotic Cultures 134 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic culture (FloraMax, IVS‐Wynco LLC) administered via oral gavage 1 hour post SH challenge.
Trial: 14970962
Drug: regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: regular therapy
Trial: 14970962
Drug: control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (no therapy)
Trial: 9256515
Drug: Direct treatment
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct treatment
Trial: 30582880
Drug: Chitosan brush
RxNorm normalized name: Chitosan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan brush treatment
Trial: 30582880
Drug: Titanium curettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium curettes treatment
Trial: 24621064
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ10) supplementation (500 mg/day)
Trial: 22385121
Drug: 5% permethrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% permethrin cream (twice application with a 1-week interval)
Trial: 22385121
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (single dose)
Trial: 11837056
Drug: Back school
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back school with peer support (treatment group, n = 47)
Trial: 10023644
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin infusion, 100 mL/d for 7 days
Trial: 520164
Drug: Systemic forms
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic forms of administration (i.v. and i.m.)
Trial: 18300848
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg/day
Trial: 30973207
Drug: Nifedipine-GITS 30-60
RxNorm normalized name: nifedipine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine-GITS 30-60 mg/day
Trial: 30973207
Drug: Amlodipine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (after missing a dose)
Trial: 29121269
Drug: FSH dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH dose of 100 IU/day
Trial: 29121269
Drug: FSH dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSH dose of 150 IU/day
Trial: 23374559
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (daily for 6 months)
Trial: 19383582
Drug: Pentoxifylline (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (800 mg/day orally) for 5 days before surgery
Trial: 29888582
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (electroacupuncture, acupoint-injection, fire-needle)
Trial: 23422097
Drug: Combined subfascial
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined subfascial endoscopic perforator surgery (SEPS) and endovenous laser treatment (EVLT)
Trial: 20440528
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of bovine type II collagen (bCII)
Trial: 20440528
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of bovine type II collagen (bCII)
Trial: 20440528
Drug: 0.05 mg
RxNorm normalized name: biotin 0.05 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg of bovine type II collagen (bCII)
Trial: 17009230
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with MTX plus etanercept
Trial: 10921554
Drug: Oxidized‐raffinose cross‐linked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxidized‐raffinose cross‐linked human hemoglobin (Hemolink) at doses of 0.025-0.6 g/kg
Trial: 8612381
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) for 7 days
Trial: 8612381
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of terfenadine (60 mg twice a day) with grapefruit juice (240 ml) 2 hours after terfenadine for 7 days
Trial: 6749189
Drug: Anticholinergic agent
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic agent (atropine methonitrate)
Trial: 6749189
Drug: Adrenergic agent
RxNorm normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic agent (salbutamol)
Trial: 6749189
Drug: Anticholinergic agent
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic agent first
Trial: 6749189
Drug: Adrenergic agent
RxNorm normalized name: ANTIADRENERGIC AGENTS, CENTRALLY ACTING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenergic agent first
Trial: 26821876
Drug: Bilateral transversus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral transversus abdominis plane block using 21 ml of 0.25% bupivacaine and 4.0 mg dexamethasone
Trial: 26821876
Drug: Parenteral opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral opioids alone (sham block with 21 ml 0.9% saline)
Trial: 22517769
Drug: ROSE-010 100
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 100 μg
Trial: 22517769
Drug: ROSE-010 300
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 300 μg
Trial: 22517769
Drug: ROSE-010 30
RxNorm normalized name: Rose Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 30 μg
Trial: 22517769
Drug: ROSE-010 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROSE-010 (all doses)
Trial: 12236441
Drug: 7.6% carbohydrate‐electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.6% carbohydrate‐electrolyte solution (CES)
Trial: 11016338
Drug: Pneumoperitoneum (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumoperitoneum (1200 mL of air injected under the right hemidiaphragm)
Trial: 1462894
Drug: Recombinant tissue‐type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue‐type plasminogen activator (rTPA), 1 mg/kg body weight (maximum 100 mg) during 4 hours, in addition to aspirin, heparin, and beta‐blockade
Trial: 6376484
Drug: Isocarboxazid (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocarboxazid (active medication)
Trial: 30670279
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (10 days of oral vitamin A)
Trial: 27121115
Drug: High-selenium lentils
RxNorm normalized name: HIGH SELENIUM YEAST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-selenium lentils (65 g per day for 6 months)
Trial: 27121115
Drug: Low-selenium lentils
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-selenium lentils (65 g per day for 6 months)
Trial: 24520782
Drug: Hydrocortisone edema
RxNorm normalized name: hydrocortisone Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone edema solution
Trial: 16398599
Drug: Soy +
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy + probiotic capsules
Trial: 16398599
Drug: Milk +
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk + probiotic capsules
Trial: 12087922
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg tablet (test formulation)
Trial: 12087922
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg tablet (reference formulation)
Trial: 10617243
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg simvastatin/d for 6 weeks
Trial: 10617243
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg simvastatin/d for 6 weeks
Trial: 8538903
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg/die (Group A, n = 10)
Trial: 8538903
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die (Group B, n = 20)
Trial: 8538903
Drug: Lisinopril 20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 20 mg/die + Nitrendipine 20 mg/die (Group C, n = 10)
Trial: 31233281
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg plus MTX
Trial: 23114828
Drug: FP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP with the conventional rigid bar splinting the implants
Trial: 17146370
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) regimens including > or =3 agents
Trial: 9586422
Drug: Bromocriptine (Br)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (Br) 2.5 mg po at time -60
Trial: 8575494
Drug: Etretinate 25
RxNorm normalized name: etretinate 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etretinate 25 mg orally each day
Trial: 2773665
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion after ibuprofen
Trial: 2773665
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion after ibuprofen
Trial: 19690306
Drug: Nursing-led psychoeducational
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing-led psychoeducational intervention (Project ENABLE) consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161)
Trial: 9119635
Drug: BCG treatment
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatment (150 mg Pasteur BCG per instillation, 6-week induction course, single maintenance doses for 2 years)
Trial: 9119635
Drug: Epirubicin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin treatment (50 mg per instillation, early instillation on postoperative day 2, followed by 4 weekly treatments and 10 monthly treatments for 2 years)
Trial: 9119635
Drug: BCG treatment
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG treatment in patients with stage T1 and grade 3 tumours
Trial: 1394824
Drug: Intravenous methotrexate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M‐VAC)
Trial: 1394824
Drug: Factors analyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors analyzed included performance status (PS), M category, and dose of drugs
Trial: 29341404
Drug: canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: canagliflozin 100 mg
Trial: 29341404
Drug: canagliflozin 200
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: canagliflozin 200 mg
Trial: 24915612
Drug: peginterferon alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon alfa‐2a 180 μg/week
Trial: 2243896
Drug: Methysergide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methysergide (4 mg p.o.)
Trial: 8981385
Drug: Metergoline (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metergoline (4 mg p.o.)
Trial: 2243896
Drug: MCPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCPP (0.5 mg/kg p.o.)
Trial: 445772
Drug: Persistent medical
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent medical therapy
Trial: 31562005
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B birth dose (HepB- BD)
Trial: 23921271
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 µg/kg/min after a loading dose of 12 µg/kg)
Trial: 8193735
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg o.d.
Trial: 8193735
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg o.d. as basic antihypertensive treatment
Trial: 3989697
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tablet formulation
Trial: 3989697
Drug: syrup formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: syrup formulation
Trial: 3989697
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tablet formulation with different inactive excipients
Trial: 29461870
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (PR2.3.1)
Trial: 25630582
Drug: Topical spot-on
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical spot-on formulation containing 6.76% w/v fipronil + 50.48% w/v permethrin
Trial: 18565817
Drug: Selenium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium therapy (L-seleno-methionine 2 x 100 microg/day for one year)
Trial: 18565817
Drug: Selenium therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium therapy
Trial: 15717211
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of sarizotan
Trial: 3404814
Drug: Arginine HCl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arginine HCl, 250 mg/kg infused over 30 minutes
Trial: 3404814
Drug: Indomethacin, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 150 mg
Trial: 3160915
Drug: Ibuprofen, 800
RxNorm normalized name: Ibuprofen, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 800 mg
Trial: 3404814
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no cyclooxygenase inhibitors)
Trial: 3404814
Drug: Indomethacin, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin, 150 mg before second infusion of arginine
Trial: 21949643
Drug: Standard antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiretroviral therapy (ART)
Trial: 21310502
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT); 39 patients/44 feet, twice per week for 6 treatments
Trial: 21310502
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT); 38 patients/40 feet, daily for 20 treatments
Trial: 15606437
Drug: Cetirizine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine at 0.25 mg kg(‐1) twice daily for 18 months
Trial: 15606437
Drug: Levocetirizine 0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 0.125 mg kg(‐1) twice daily
Trial: 29625591
Drug: Antiretroviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment (ART) with an age-appropriate stimulation program, updated at 3 monthly intervals through the first year of life.
Trial: 26517283
Drug: High-dose (HD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (HD) factor VIII (200 IU kg‐1 day‐1)
Trial: 26517283
Drug: Low-dose (LD)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (LD) factor VIII (50 IU kg‐1 3× per week)
Trial: 22168137
Drug: Weekly TM-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly TM-based feedback with goal setting
Trial: 22168137
Drug: Weekly TM-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly TM-based drinking assessments without feedback
Trial: 19660970
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of Hormone Replacement Therapy (HRT)
Trial: 9927002
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (500 mg, 2 times a day for 48 h)
Trial: 342594
Drug: Naftidrofuryl (Praxilene)
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (Praxilene) 300 mg per day
Trial: 28479852
Drug: DWP05195 (10-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP05195 (10-600 mg single dose; 100-400 mg once daily for 8 days)
Trial: 28479852
Drug: DWP05195 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP05195 (multiple doses)
Trial: 28479852
Drug: DWP05195 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP05195 (up to 600 mg single dose; 400 mg multiple dose)
Trial: 19384179
Drug: De novo
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De novo sirolimus-based therapy without calcineurin inhibitors
Trial: 19384179
Drug: Initial use
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial use of a calcineurin inhibitor for 2 to 4 months followed by conversion to sirolimus
Trial: 19384179
Drug: Late withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late withdrawal of steroids
Trial: 14598251
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with Photofrin 2 mg/kg body weight, administered intravenously 2 days before intraluminal photoactivation (wavelength, 630 nm; light dose, 180 J/cm²)
Trial: 8986544
Drug: Transmandibular implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transmandibular implant (TMI) with a triple bar and cantilever extensions, provided with an overdenture
Trial: 8986544
Drug: Intramobile cylinder
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramobile cylinder implants (IMZ) connected by a Dolder bar, provided with an overdenture
Trial: 1729935
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and placebo intravenously after induction
Trial: 1729935
Drug: Oral transmucosal
RxNorm normalized name: Thrive, 2 mg oral transmucosal gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral transmucosal fentanyl citrate (OTFC) 15-20 micrograms/kg lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Trial: 1729935
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge 45 min preoperatively and placebo (normal saline) injected intravenously after induction
Trial: 1729935
Drug: Placebo lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenge 45 min preoperatively and droperidol 50 micrograms/kg intravenously after induction
Trial: 29278428
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) plus G‐CSF 3 monthly plus GH daily (group A; n = 23)
Trial: 29278428
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) plus G‐CSF (group B; n = 21)
Trial: 29278428
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone (group C; n = 21)
Trial: 26991619
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion (initial bolus of 0.25 μg/kg and infusion of 0.25 μg/kg/min)
Trial: 20346565
Drug: Bioadhesive 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive 0.2% CHX gel applied intraoperatively once after surgical removal of the third molar
Trial: 20346565
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel applied in an identical fashion
Trial: 20346565
Drug: Bioadhesive 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioadhesive 0.2% CHX gel
Trial: 16259543
Drug: Olanzapine (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (6-12 mg/day) plus fluoxetine (25-50 mg/day) combination
Trial: 16259543
Drug: Olanzapine (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (6-12 mg/day)
Trial: 16259543
Drug: Fluoxetine (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (25-50 mg/day)
Trial: 16259543
Drug: Nortriptyline (25-175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (25-175 mg/day)
Trial: 16259543
Drug: Olanzapine/fluoxetine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/fluoxetine combination (subgroup analysis)